T
Tudor-Eliade Ciuleanu
Researcher at Iuliu Hațieganu University of Medicine and Pharmacy
Publications - 8
Citations - 4119
Tudor-Eliade Ciuleanu is an academic researcher from Iuliu Hațieganu University of Medicine and Pharmacy. The author has contributed to research in topics: Lung cancer & Necitumumab. The author has an hindex of 3, co-authored 8 publications receiving 3096 citations. Previous affiliations of Tudor-Eliade Ciuleanu include Babeș-Bolyai University.
Papers
More filters
Journal ArticleDOI
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
Matthew D. Hellmann,Tudor-Eliade Ciuleanu,Adam Pluzanski,Jong-Seok Lee,Gregory A. Otterson,Clarisse Audigier-Valette,Elisa Minenza,Helena Linardou,Sjaak Burgers,Pamela Salman,Hossein Borghaei,Suresh S. Ramalingam,Julie R. Brahmer,Martin Reck,Kenneth J. O'Byrne,William J. Geese,George Green,Han Chang,Joseph D. Szustakowski,Prabhu Bhagavatheeswaran,Diane Healey,Yali Fu,F. E. Nathan,Luis Paz-Ares +23 more
TL;DR: The benefit of nivolumab plus ipilimumab over chemotherapy was broadly consistent within subgroups, including patients with a PD‐L1 expression level of at least 1% and those with a level of less than 1%.
Journal ArticleDOI
First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
David P. Carbone,Martin Reck,Luis Paz-Ares,Benjamin C. Creelan,Leora Horn,Martin Steins,Enriqueta Felip,Michel M. van den Heuvel,Tudor-Eliade Ciuleanu,Firas Benyamine Badin,Neal Ready,T. Jeroen N. Hiltermann,Suresh G. Nair Md,Rosalyn A. Juergens,Solange Peters,Elisa Minenza,John Wrangle,Delvys Rodriguez-Abreu,Hossein Borghaei,George R. Blumenschein,Liza C. Villaruz,Libor Havel,Jana Krejci,Jesus Corral Jaime,Han Chang,William J. Geese,Prabhu Bhagavatheeswaran,Allen C. Chen,Mark A. Socinski +28 more
TL;DR: Nivolumab was not associated with significantly longer progression‐free survival than chemotherapy among patients with previously untreated stage IV or recurrent NSCLC with a PD‐L1 expression level of 5% or more.
Journal ArticleDOI
A multicenter, single-arm, basket design, phase II study of NC-6004 plus gemcitabine in patients with advanced unresectable lung, biliary tract, or bladder cancer.
Simona Ruxandra Volovat,Tudor-Eliade Ciuleanu,Piotr Koralewski,Juneko E. Grilley Olson,Adina Croitoru,Krassimir Koynov,Stefano Stabile,Giulio Cerea,Atsushi Osada,Iulian Bobe,Constantin Volovat +10 more
TL;DR: Overall, combined NC-6004 and gemcitabine treatment resulted in long-lasting antitumor activity and had a favorable safety profile, suggesting that it should be investigated further as a therapy for various types of cancer.
Journal ArticleDOI
Cardiomyopathies and Arrhythmias Induced by Cancer Therapies
Dragoș-Mihai Romitan,Dan Radulescu,Ioana Berindan-Neagoe,L. Stoicescu,Alin Grosu,Liliana Radulescu,Diana Gulei,Tudor-Eliade Ciuleanu +7 more
TL;DR: The present review provides essential information summarized from the latest studies from cardiology, oncology, and hematology to bring together the three specialties and offers proper management options for oncological patients.
Journal ArticleDOI
1232psquire: a randomized, multicenter, open-label, phase iii study of gemcitabine-cisplatin (gc) chemotherapy plus necitumumab (imc-11f8/ly3012211) vs gc alone in the first-line treatment of patients (pts) with stage iv squamous non-small cell lung cancer (sq-nsclc): update on key subgroups
Mark A. Socinski,Luis Paz-Ares,Alexander Luft,Aleksandra Szczesna,Tudor-Eliade Ciuleanu,W. Szafranski,Martin Reck,B. Balint,K. Park,C. Schumann,Fred R. Hirsch,H. Depenbrock,S. Nanda,Nadia Chouaki,Nick Thatcher +14 more
TL;DR: GC + N demonstrated improved OS, with an acceptable safety profile, across all subgroups, and the addition of N to GC statistically significantly improved OS (HR = 0.84), and the safety profile of GC + N was acceptable across subgroups.